Core Viewpoint - Silver诺医药-B (02591) has seen its stock price increase by over 5%, marking three consecutive days of gains, currently trading at 43.42 HKD with a transaction volume of 7.6433 million HKD [1] Group 1: Stock Performance - The stock price of Silver诺医药-B has risen by 5.03% [1] - The current trading price is 43.42 HKD [1] - The transaction volume reached 764.33 million HKD [1] Group 2: Market Inclusion - Silver诺医药 has been included in the Hang Seng Composite Index as part of the quarterly review results [1] - The change will take effect on December 8, 2025 [1] Group 3: Company Overview - Silver诺医药 is focused on the field of metabolic diseases [1] - The company has multiple innovative drug development pipelines targeting diabetes, obesity, and non-alcoholic fatty liver disease [1] - All drugs are self-developed and possess global intellectual property rights, with a comprehensive global research and market layout [1]
银诺医药-B再涨超5% 下周一正式进入恒生综指 机构称其符合港股通纳入范围